More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

MSK-PCa5: Human Prostate Cancer Organoids

Description

The organoids were from CD45 depleted buffy coat, and showed small and showed diffusely positive pan-cytokeratin and variable AR staining. The established organoid line exhibits a double time of 1 week.

Source

MSK-PCa5 is developed from a patient who developed widespread metastatic disease only five months after prostatectomy for radiographically localized Gleason 4+5 prostate cancer. He had a brief PSA response to ADT and a subsequent sustained PSA response to abiraterone acetate despite radiographic progression of disease.

Inventors

  • Yu Chen, MD, PhD,  Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
  • Dong Gao, PhD, formerly at Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center

Key References

Gao D, et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell,  2014;159(1):176-87.

Licensing Information

This organoid cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

Stage of Development

Ready to use

Indications